ACT-02 Changes in Recurrence Pattern and Prognosis of Glioblastoma after Approval of Bevacizumab as First-line Application

Introduction: There exist controversies on recurrence and aggressiveness after use of first-line bevacizumab (BEV) which has been approved in Japan and proven to be beneficial. Therefore, we analyzed the clinical impact of BEV approval by investigating the overall clinical course and glioblastoma (G...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neurooncol Adv
Main Authors: Funakoshi, Yusuke, Hata, Nobuhiro, Kuga, Daisuke, Hatae, Ryusuke, Sangatsuda, Yuhei, Fujioka, Yutaka, Takigawa, Kosuke, Mizoguchi, Masahiro
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Supplement Abstracts
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7699102/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa143.032
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki